Step therapy blocked your GLP-1? “Fail first” has exceptions.
Step therapy means the plan wants you to try — and fail — a cheaper drug before it covers the one your prescriber chose. GLP-1s trigger it constantly: more than 90% of commercial plans require prior authorization for GLP-1 weight-loss drugs, and a 2026 JAMA study of over 2 million prescription attempts found they were initially rejected at the pharmacy about 85% of the time — the highest of any drug class studied.
But “fail first” is not absolute. There are five recognized exception grounds, and the evidence for most of them already lives in your prescriber’s chart. Upload your denial — Lysco identifies which ground fits your situation and drafts the appeal. Your first read is free.
Free to see exactly what’s wrong. $9 to unlock the full appeal — only if you choose to proceed. No subscription.
The exception grounds
Five recognized ways around “fail first” — and what proves each
Step-therapy overrides are granted on specific, recognized grounds. Each one turns on documentation, not persuasion — the appeal’s job is to match your record to the right ground and quote it.
You already tried the required drug — and it failed
What proves it: Chart notes showing the drug name, start and stop dates, the dose you reached, how long the trial lasted, and the documented outcome. Trials completed under a previous insurer or paid for in cash count clinically — but only if the chart shows them, because the plan’s automated check usually can’t see them.
The required drug is contraindicated for you
What proves it: The specific condition or interacting medication in your chart that makes the required drug inappropriate, plus a prescriber statement naming the contraindication. This ground does not require you to take the drug at all.
The required drug is expected to cause you harm
What proves it: Broader than a formal contraindication: documented adverse effects from the same or a similar drug, or risk factors in your history, with a prescriber statement explaining the expected harm.
You are stable on your current drug
What proves it: Records showing you are already established and doing well on the prescribed drug — for example after starting through samples, a manufacturer program, or a previous plan. The documentation is your current therapy, its duration, and the charted clinical response; forcing a switch mid-treatment is what the exception addresses.
The required drug is not in the same class — or does not fit your indication
What proves it: A prescriber statement on what condition is actually being treated and why the required step drug is not appropriate for it. This comes up with GLP-1s because labels differ: Wegovy carries a cardiovascular risk-reduction indication and Zepbound an obstructive sleep apnea indication — if that is the condition being treated, a generic weight-loss step drug may not fit the indication at all.
Whether any of these grounds applies to you is a decision for you and your doctor. Drug-specific angles live in the Wegovy guide and the Zepbound guide.
Build the record
What counts as a “documented failure”
“I tried it and it didn’t work” is a sentence. A documented failure is a record. Plans generally look for three things, and your prescriber’s chart is the evidence — the appeal quotes it, with dates:
Adequate trial duration — you stayed on the drug long enough for a fair trial. Plans usually define a minimum length in their written step-therapy policy; the appeal compares your trial against the plan’s own number, so request that policy in writing.
Dose reached — the chart shows the drug was titrated toward a therapeutic dose, not stopped at the starting dose. A trial abandoned at the lowest dose is the most common reason plans call documentation “insufficient.”
A documented reason for stopping — lack of clinical response recorded in the chart, adverse effects your prescriber noted, or another documented medical reason. The reason matters as much as the stopping.
Your rights
The exception clock, external review, and state override laws
The federal exception clock: for marketplace and other essential-health-benefit plans, 45 CFR 156.122 requires a decision on a formulary-exception request within 72 hours for a standard request and 24 hours when expedited for urgent situations. If the plan denies the exception, that denial can go to an independent external review — a reviewer who does not work for your insurer.
State override laws: more than 30 states have laws requiring insurers to grant step-therapy exceptions in defined circumstances — the grounds above track them closely. Protections and covered plan types vary by state, so check your state insurance department for what applies to your plan.
One high-level difference worth knowing: Medicare Part D excludes weight-loss drugs by statute, so what looks like a step-therapy problem on a Part D plan is often really a coverage exclusion — a different appeal. State Medicaid programs set their own prior-authorization and step-therapy rules, which vary by state. Your denial notice names the plan type and the process that applies.
Deadlines are real, and they are the only reason to hurry: commercial and ACA plans generally allow 180 days from the denial to file an internal appeal, while Medicare Part D deadlines can be as short as 60 days. Your denial notice states yours.
Denial playbook
The three step-therapy denial wordings — and what answers each
“Coverage requires trial and failure of a preferred alternative”
The classic fail-first denial. If you already completed a qualifying trial, the appeal documents it from your chart — dates, dose, duration, outcome. If you haven’t, check the other exception grounds first: contraindication, expected harm, stability on your current drug, and an indication mismatch don’t require you to take the step drug at all.
“Submitted documentation does not establish an adequate trial”
The plan saw a trial but says it was too short, the dose too low, or the outcome unrecorded. The answer is the chart itself: the appeal quotes start and stop dates, the titration, the documented response, and the reason for stopping — then compares that against the plan’s own written trial-length requirement, which you can request in writing.
“A formulary alternative is available”
The plan is pointing at a different drug it prefers. The standard route is a formulary-exception request with your prescriber’s clinical justification for why the alternatives are not appropriate — a prior failure, a contraindication, or an indication the alternative doesn’t cover. Marketplace and other essential-health-benefit plans must decide within 72 hours (24 if expedited), and a denied exception can go to external review.
Honest odds: in 2024 ACA Marketplace data (KFF), fewer than 1% of denied in-network claims were formally appealed — and of the appeals that were filed, about 1 in 3 ended with the denial overturned internally. Those are population numbers, not a prediction for your case; outcomes depend on your plan, denial reason, and documentation. Nobody can promise your appeal will win — anyone who does is selling something.
Questions
Step-therapy questions, answered straight
What is step therapy?
Step therapy — often called “fail first” — is a plan rule that requires you to try one or more preferred, usually cheaper, drugs before the plan will cover the one your prescriber chose. Skip the required step and the claim is denied automatically at the pharmacy or during prior authorization. The rule is not absolute: recognized exception grounds — a documented failed trial, a contraindication, expected harm, stability on your current drug, or a required drug that does not fit your condition — can qualify you for an override.
I already tried and failed the cheaper drug. Why was I still denied?
Usually because the plan never saw the evidence. Automated step-therapy checks typically look at your claims history with that plan — a trial you completed under a previous insurer, paid cash for, or that only exists in your prescriber’s chart notes is often invisible to the system. The fix is documentation: chart notes showing the drug, the dates, the dose you reached, how long the trial lasted, and why it was stopped. An appeal or formulary-exception request puts that record in front of a human reviewer.
How fast does my plan have to decide an exception request?
For marketplace and other essential-health-benefit plans, federal rules at 45 CFR 156.122 require a decision on a formulary-exception request within 72 hours for a standard request — and within 24 hours when expedited for urgent situations. If the exception is denied, that denial can go to an independent external review. Other plan types set their own clocks; your denial notice and plan documents state the deadlines that apply to you.
How much does Lysco cost?
Your first read is free — upload the denial and see exactly which exception ground fits your situation, if any. If you proceed, it is a flat $9 to unlock the full ready-to-sign appeal and submission instructions. No subscription, no credit card to start.
Start your step-therapy appeal — free
Your first read is free. 30 seconds to upload. No credit card needed.
Appeal my step-therapy denialEncrypted in transit and at rest · Access controlled · Delete anytime
Lysco is an informational tool — not a law firm, medical provider, or licensed patient advocate. We don’t prescribe or recommend medications; whether any drug or exception ground applies to you is a decision for you and your doctor. You review, sign, and submit anything you choose to use — Lysco never contacts your insurer. Appeal outcomes vary by plan, diagnosis, documentation, and circumstances. This page is not medical or legal advice. Drug names are trademarks of their respective manufacturers.